For a patient in a neuro-ICU with a traumatic brain injury, the most critical piece of information is also the most dangerous to obtain. Intracranial pressure (ICP),the force exerted by cerebrospinal fluid inside the skull,is a vital sign for preventing secondary brain damage. Today, knowing that number requires drilling a small hole through the skull to insert a pressure sensor, a surgical procedure with risks of bleeding, infection, and further injury. It is a necessary, invasive gamble. CranioView, a San Francisco-based startup founded in 2020, is betting it can change that calculus with a wearable device that reads pressure through the eye [cranioview.com]. The company is developing a noninvasive monitor that uses ocular ultrasound and machine learning, aiming to give clinicians continuous, safe data on a patient’s most fragile organ.
The Technical Wedge: Ultrasound Through the Orbital Window
The company’s technical approach focuses on a specific anatomical gateway. Its device uses transcranial Doppler ultrasonography (TCD-US) to image the ophthalmic artery and other vessels behind the eye [cranioview.com]. These vessels are influenced by intracranial pressure, and their pulsatile characteristics can serve as a proxy measurement. CranioView’s proposed innovation is to pair this ultrasound data with machine learning models to interpret the signal and produce an accurate, continuous ICP readout, all from a wearable form factor. The goal is a self-calibrating system that eliminates the need for surgery [cranioview.com]. For neurocritical care teams, the promise is profound: the ability to monitor pressure trends in real-time, to guide treatment decisions on fluid management or sedation, without introducing new procedural risks.
An Early-Stage Bet With Academic Roots
CranioView operates with a lean team, estimated at one to ten employees [Prospeo]. Its co-founders bring a physician-engineer blend common in translational medtech. Gil Herrnstadt, the CEO, lists a background in medical robotics and translational research [LinkedIn]. His co-founder, Neil R. Parikh, is a physician with experience in healthcare consulting [cranioview.com]. The company’s early development has been supported by academic incubation, having participated in the Magnify Incubator at UCLA’s California NanoSystems Institute (CNSI) and listing UCLA among its investors [F6S]. This suggests the foundational research may have origins within the university’s biomedical engineering or neurology departments, though the company has not disclosed specific trial data or regulatory pathways.
| Role | Name | Background |
|---|---|---|
| Co-founder, CEO | Gil Herrnstadt | Medical robotics, translational research [LinkedIn]. |
| Co-founder | Neil R. Parikh, MD MBA | Physician, healthcare consulting [cranioview.com]. |
The Regulatory and Clinical Hurdle Ahead
The ambition is clear, but the path to the ICU bedside is long and steep. The primary challenge is clinical validation. For a device making a claim as critical as noninvasive ICP monitoring, the burden of proof to the FDA or other regulators is exceptionally high. The machine learning algorithm must be trained and validated on gold-standard data from invasive monitors, requiring access to a sensitive patient population and rigorous clinical study design. CranioView has not publicly disclosed any such trials, peer-reviewed publications, or regulatory submissions. Furthermore, it is not the only company pursuing this goal.
- Clinical validation. The single greatest risk is proving the device’s accuracy and reliability matches or exceeds the current invasive standard across a diverse patient population. Without published data, the technology remains a compelling concept.
- Competitive landscape. Other firms, like Integra LifeSciences with its noninvasive ICP monitoring business, have also explored the space, indicating established players see the value but have yet to achieve widespread adoption of a noninvasive solution.
- Commercial adoption. Even with regulatory clearance, convincing neuro-ICUs to adopt a new monitoring paradigm requires demonstrating not just safety and efficacy, but also workflow integration and cost-effectiveness compared to a familiar, if invasive, standard.
For patients with severe traumatic brain injury, stroke, or brain hemorrhage, the current standard of care is a stark reality. Management in the neuro-ICU often involves sedation, mechanical ventilation, and the invasive placement of an ICP monitor. The procedure, while routine in specialized centers, carries inherent risks and is not suitable for all patients, particularly those who are too unstable for surgery or who need monitoring for longer periods. CranioView’s target is this precise, vulnerable population: individuals suffering from acute neurological injuries where continuous pressure data could mean the difference between recovery and catastrophic decline. The company’s entire bet rests on replacing a risky surgical step with a gentle scan, turning the eye into a window for the brain’s most guarded secret.
Sources
- [cranioview.com] About | https://www.cranioview.com/about
- [LinkedIn] Gil Herrnstadt | LinkedIn | https://www.linkedin.com/in/gilherrnstadt
- [Prospeo] CranioView Email Format & Contact Info | https://prospeo.io/c/cranioview-email-format
- [F6S] CranioView | F6S | https://www.f6s.com/company/cranioview
- [ZoomInfo.com] CranioView - Overview, News & Similar companies | ZoomInfo.com | https://www.zoominfo.com/c/cranioview/537121208